EMAIL THIS PAGE TO A FRIEND

Morphologie : bulletin de l'Association des anatomistes

Osteomalacia in a patient with Paget's bone disease treated with long-term etidronate.


PMID 23022200

Abstract

A 93 year-old woman with Paget's disease of bone had been treated with etidronate without interruption during 20 years. The daily dose was usual (5mg/kg/day) but this prescription had never been stopped by her physicians. Two fractures had already occurred in pagetic (right tibia) and non pagetic bones (right fibula) within the last 2 years, and she presented rib fractures, another right tibia fracture and right femur fracture during hospitalization time. X-rays films showed major osteolysis of left ulna and right tibia. Blood samples and technetium bone scan brought no evidence for sarcoma or lytic evolution of the disease. A transiliac bone biopsy on non pagetic bone site confirmed the diagnosis of osteomalacia (increased osteoid parameters), with secondary hyperparathyroidism (hook resorption). In Paget's disease of bone, continuous treatment by etidronate may induce generalized osteomalacia, and increase the risk of fracture in both pagetic and non-pagetic bones. Whereas physicians and pharmaceutical industry try to improve the observance of those drugs, this striking observation also points out that a prescription always needs to be updated.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

P5248
Etidronate disodium hydrate, ≥97% (NMR), solid
C2H6Na2O7P2 · xH2O
H6773
Etidronic acid, 60% aqueous solution
C2H8O7P2